论文部分内容阅读
目的观察联合应用乌司他丁(UTI)和奥曲肽治疗重症急性胰腺炎(SAP)的疗效。方法将56例重症急性胰腺炎患者按就诊顺序随机分为治疗组(UTI+奥曲肽)和对照组(奥曲肽),每组28例,观察治疗前后患者的临床症状、体征、血尿淀粉酶和血清中白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平。结果治疗组可显著改善SAP患者的临床症状体征、降低血尿淀粉酶及血清IL-6、TNF-α水平,提高临床治愈率及总有效率,优于对照组(P<0.05或0.01)。结论UTI和奥曲肽联合治疗可降低SAP患者的炎症性细胞因子,明显提高重症急性胰腺炎的疗效。
Objective To observe the curative effect of combined use of ulinastatin (UTI) and octreotide in the treatment of severe acute pancreatitis (SAP). Methods Fifty-six patients with severe acute pancreatitis were randomly divided into treatment group (UTI + octreotide) and control group (octreotide), with 28 cases in each group. Clinical symptoms and signs, hematuria, amylase and serum leukocyte Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) levels. Results The treatment group can significantly improve clinical symptoms and signs of SAP patients, reduce the level of serum amylase, serum IL-6 and TNF-α, improve the clinical cure rate and total effective rate, which is better than the control group (P <0.05 or 0.01). Conclusions Combination of UTI and octreotide can reduce the inflammatory cytokines in SAP patients and significantly improve the efficacy of severe acute pancreatitis.